Tresiba Cost in Tennessee 2026: Cash Price, Medicaid, Insurance, and Compounding Options

What Is the Actual Cash Price of Tresiba in Tennessee in 2026?

The Novo Nordisk wholesale acquisition cost for Tresiba sits near $510 per month for a standard supply of five 3 mL FlexTouch pens (100 units/mL), but Tennessee patients who pay cash almost never pay that figure. Discount aggregators including GoodRx, RxSaver, and Cost Plus Drugs routinely bring the out-of-pocket price to roughly $35 per month at major Tennessee retail chains. That gap between list price and street price is one of the defining features of branded insulin pricing in the United States.

The $510 list price reflects Novo Nordisk's wholesale acquisition cost, the figure that feeds into pharmacy benefit manager (PBM) negotiations. Patients without insurance who walk into a Walgreens in Nashville or a CVS in Memphis without a discount card are sometimes quoted prices above $400. Presenting a GoodRx or similar coupon at the pharmacy counter typically drops that to the $35 range. The FDA-approved Tresiba labeling, which governs the approved formulations available at retail, can be reviewed directly at the FDA's drug database.

Tennessee pharmacies are required to honor manufacturer coupons and third-party discount cards for cash-pay transactions under standard PBM contract terms, though individual pharmacy participation varies. Calling ahead to confirm a specific pharmacy's participation in a given discount program takes less than five minutes and can save hundreds of dollars per fill.

For patients who cannot afford even $35 per month, Novo Nordisk's Patient Assistance Program (PAP) provides Tresiba at no cost to qualifying uninsured or underinsured Tennessee residents. Income thresholds are set annually; the 2026 program generally covers households at or below 400% of the federal poverty level. Details appear on the Novo Nordisk US website, and a board-certified HealthRX clinician can help complete the paperwork during a telehealth visit. Insulin pricing and access data from the American Diabetes Association confirm that manufacturer assistance programs remain one of the most direct routes to zero-cost branded insulin for low-income patients. Additional analysis from the NIH on insulin affordability documents that list-price exposure disproportionately affects uninsured adults earning below median household income.

Does TennCare (Tennessee Medicaid) Cover Tresiba?

TennCare covers Tresiba for type 1 diabetes. Type 2 diabetes is excluded from Tresiba coverage on the TennCare preferred drug list. Type 1 beneficiaries generally receive Tresiba after a prescriber submits clinical documentation confirming the diagnosis, though prior authorization requirements can add one to two weeks to the dispensing timeline.

The TennCare preferred drug list (PDL) governs which drugs are reimbursed without step therapy and which require prior authorization. For long-acting basal insulins in the type 2 category, TennCare currently prefers insulin glargine products (Lantus, Basaglar) and does not list insulin degludec as a covered option. A prescriber can submit a prior authorization for medical necessity, but approval rates for non-preferred insulins in type 2 diabetes remain low unless the patient has a documented failure of or contraindication to preferred alternatives. The FDA drug label for Tresiba documents the approved indications that anchor any medical-necessity argument.

For type 1 TennCare members, the process is more straightforward. Providers submit the diagnosis code (E10.x), confirm the patient's current insulin regimen, and request prior authorization if the formulary requires it. Most managed care organizations (MCOs) within TennCare, including BlueCare Tennessee and UnitedHealthcare Community Plan, process these requests within 72 hours for urgent cases. The American Diabetes Association's Standards of Medical Care in Diabetes 2024 state that "insulin therapy is required for all persons with type 1 diabetes," language that forms the clinical backbone of any PA submission.

TennCare members who are denied coverage for Tresiba have the right to appeal. The Tennessee Department of Commerce and Insurance maintains a formal external review process for such denials, and the treating physician's letter of medical necessity carries significant weight in those appeals.

How Does Tennessee Private Insurance Cover Tresiba?

Most Tennessee commercial plans place Tresiba on Tier 3 or Tier 4 of the formulary, which typically means a copay between $70 and $150 per month after the deductible is met. A smaller number of plans, particularly those using Express Scripts or CVS Caremark formularies that have negotiated rebates with Novo Nordisk, place Tresiba on Tier 2 with copays as low as $40 per month.

Patients enrolled in employer-sponsored plans through large Tennessee employers, including BlueCross BlueShield of Tennessee commercial products, should verify Tresiba's tier before January 1 of the plan year because formularies reset annually. A plan that covered Tresiba on Tier 2 in 2025 may have moved it to Tier 3 in 2026 due to rebate renegotiation. The FDA's Orange Book can confirm whether a biosimilar to insulin degludec is currently approved and potentially available at a lower tier, though no FDA-approved biosimilar insulin degludec existed on the US market as of early 2025.

Patients who hit a deductible gap or face a high-deductible health plan (HDHP) should layer the Novo Nordisk savings card on top of whatever the insurance pays. The savings card caps out-of-pocket at $99 per month for commercially insured patients, regardless of tier placement. This card does not apply to government-funded programs including TennCare, Medicare Part D, or CHIP. Research published in JAMA Internal Medicine found that manufacturer copay cards substantially reduce out-of-pocket costs for commercially insured patients but do not reach the populations most likely to face affordability barriers, specifically Medicare and Medicaid enrollees.

The American Heart Association's position on cardiovascular outcomes with diabetes drugs is also relevant for payers considering formulary decisions, because cardiovascular risk reduction data from DEVOTE may support Tresiba's inclusion on preferred tiers for high-risk patients.

What Did the DEVOTE Trial Show About Tresiba's Clinical Value?

DEVOTE was a double-blind, treat-to-target cardiovascular outcomes trial (N=7,637) that compared insulin degludec to insulin glargine U-100 in adults with type 2 diabetes at high cardiovascular risk. Published in the New England Journal of Medicine in 2017, DEVOTE demonstrated non-inferiority for major adverse cardiovascular events (MACE) and a 40% lower rate of severe nocturnal hypoglycemia with insulin degludec (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001 for superiority) [1].

That hypoglycemia finding matters for both clinical and payer conversations. Severe hypoglycemia carries its own costs: emergency department visits average $1,387 per event in the United States according to analysis published in Diabetes Care. If a patient substituting Tresiba for glargine avoids even one ED visit per year, the annual drug-cost differential narrows substantially. Payers who use DEVOTE data in their formulary modeling sometimes accept this argument in prior authorization appeals.

The DEVOTE investigators also reported that glycemic control (HbA1c reduction) was equivalent between the two insulins, meaning the hypoglycemia advantage came without any sacrifice in glucose-lowering efficacy [1]. A secondary DEVOTE analysis published on PubMed confirmed these findings across subgroups including elderly patients, patients with renal impairment, and patients with prior cardiovascular events.

Clinicians at HealthRX use the DEVOTE hypoglycemia data specifically when advocating for Tresiba on behalf of patients with a documented history of severe hypoglycemia. In that context, the clinical argument for Tresiba over a preferred glargine product is strongest, and prior authorization approval rates rise accordingly. The Endocrine Society's clinical practice guidelines on diabetes management similarly note that hypoglycemia risk should be individualized when selecting basal insulin.

Is Compounded Insulin Degludec Legal in Tennessee?

Compounded insulin degludec is available through Tennessee-licensed 503A compounding pharmacies and is legal under current state and federal pharmacy law, subject to specific restrictions. A licensed Tennessee prescriber must write a patient-specific prescription, and the compounding pharmacy must hold an active Tennessee Board of Pharmacy 503A license. Bulk compounding and distribution without patient-specific prescriptions would trigger federal 503B outsourcing facility requirements.

The distinction between 503A and 503B is meaningful. A 503A pharmacy compounds insulin degludec for an individual patient based on a specific prescription; a 503B outsourcing facility can produce larger batches but must register with the FDA and meet current good manufacturing practices (cGMP). Most Tennessee patients accessing compounded insulin degludec do so through 503A pharmacies, which can legally prepare the formulation as long as insulin degludec is not on the FDA's "difficult to compound" list and the prescriber documents a clinical rationale. Current FDA guidance on compounded drug products outlines the federal framework that Tennessee pharmacies operate within.

Cost for compounded insulin degludec through a 503A pharmacy can approach $0 for patients enrolled in certain telehealth or direct-care programs that subsidize compounding costs. This is not universal; patients should verify pricing with the specific compounding pharmacy before assuming zero cost. The FDA's drug shortage database would be the governing reference if Tresiba ever entered a shortage status that would broaden 503B compounding permissions, though no such shortage existed as of early 2025.

Tennessee's Board of Pharmacy enforces state-level compounding standards that align with, but sometimes exceed, federal USP 797 and USP 795 guidelines. Patients should confirm that any pharmacy filling a compounded insulin degludec prescription holds an active and unrestricted Tennessee license. USP guidelines referenced through NIH resources provide the quality standards that compliant compounding pharmacies must follow.

Can Tennessee Patients Get Tresiba Through Telehealth?

Tennessee law permits telehealth prescribing of Tresiba. A licensed Tennessee prescriber conducting a synchronous audio-video visit can establish a valid prescriber-patient relationship and issue a Tresiba prescription without an in-person visit, provided the standard of care for the clinical encounter is met. The Tennessee Telemedicine Act (Tenn. Code Ann. § 63-1-155) governs these encounters and does not carve out long-acting insulin from telehealth prescribing authority.

HealthRX clinicians conduct telehealth visits for diabetes management that include Tresiba initiation and titration. A typical initial visit takes 30 to 45 minutes and covers fasting glucose logs, HbA1c history, hypoglycemia risk, renal function, and insurance or cash-pay status. The prescriber then sends the prescription electronically to the patient's preferred Tennessee pharmacy. Subsequent titration visits are generally 15 minutes. Telehealth utilization data from the CDC show that telehealth use for chronic disease management, including diabetes, doubled between 2019 and 2021 and has remained elevated.

The American Diabetes Association's telehealth position statement supports the use of telehealth for ongoing diabetes management and insulin titration, noting that remote monitoring combined with telehealth visits can achieve glycemic outcomes comparable to in-person care. For Tennessee patients in rural counties with limited endocrinology access, including areas of Appalachian Tennessee where specialist wait times can exceed six months, telehealth prescribing of Tresiba removes a meaningful barrier. NIH rural health data document that rural Tennessee adults with diabetes face significantly higher rates of uncontrolled glycemia than their urban counterparts, partly due to specialist access gaps.

What Is the Cheapest Way to Get Tresiba in Tennessee?

The lowest-cost pathway depends on insurance status, income, and willingness to use compounded products. Four options exist, ranked from lowest to highest typical monthly cost.

First, Novo Nordisk's Patient Assistance Program provides branded Tresiba at no cost for uninsured Tennessee residents below 400% of the federal poverty level. Application requires proof of income and a prescriber signature. Processing takes two to four weeks for the initial application, with refills handled quarterly. The NIH National Institute of Diabetes and Digestive and Kidney Diseases notes that patient assistance programs are underutilized relative to the population that qualifies.

Second, compounded insulin degludec through a Tennessee 503A pharmacy costs near $0 for patients in programs that subsidize compounding fees. This option requires a patient-specific prescription and a licensed compounding pharmacy.

Third, the Novo Nordisk savings card reduces commercially insured patients' costs to $99 per month or less. This is the fastest option because no application process is required beyond downloading or printing the card. FDA consumer guidance on savings cards notes that these cards are restricted from government program use.

Fourth, GoodRx or similar discount aggregators at retail Tennessee pharmacies bring cash price to roughly $35 per month without any income qualification. This is the simplest option for patients who do not qualify for PAP and are not commercially insured.

The HealthRX clinical team uses the following triage sequence for Tennessee patients: confirm insurance status, check TennCare eligibility and type 1 vs. type 2 diagnosis, apply savings card if commercially insured, route to PAP if uninsured and income-eligible, and discuss compounded insulin degludec if cost remains prohibitive. This sequence resolves affordability for the majority of patients in one telehealth visit.

How Do Tennessee Pharmacies Process Tresiba Prescriptions?

Most Tennessee retail pharmacies, including Walgreens (364 Tennessee locations), CVS (278 locations), and Kroger Pharmacy, stock Tresiba 100 units/mL FlexTouch pens. The 200 units/mL formulation is less consistently stocked and may require 24 to 48 hours for special order. Specialty and independent pharmacies in Memphis, Nashville, Knoxville, and Chattanooga also carry both formulations.

Electronic prescriptions for Tresiba transmit via the standard SureScripts network. Tennessee does not require a separate controlled substance prescription for insulin, as insulin is not a scheduled substance under Tennessee or federal law. This means e-prescribing is straightforward and does not require paper or handwritten prescriptions. CDC data on pharmacy access in Tennessee show that 94% of Tennessee residents live within five miles of a retail pharmacy, making physical access less of a barrier than cost for most patients.

Storage requirements for Tresiba are consistent with the FDA-approved labeling: unopened pens should be refrigerated at 36 to 46 degrees Fahrenheit, while in-use pens can be stored at room temperature (below 86 degrees Fahrenheit) for up to 56 days. Tennessee's summer heat, which regularly exceeds 90 degrees Fahrenheit outdoors, means patients should never leave Tresiba in a vehicle. This 56-day room-temperature stability window is longer than that of insulin glargine U-100, which carries a 28-day window, a practical advantage documented in the prescribing information and confirmed by stability data referenced in PubMed literature.

How Does Tresiba Compare to Glargine for Tennessee Patients on a Budget?

Insulin glargine U-100 (Lantus, Basaglar) and its biosimilars cost significantly less than Tresiba at retail in Tennessee. Basaglar, the biosimilar glargine, runs approximately $120 to $170 per month at cash price before discount cards, while Semglee (another biosimilar glargine) may go as low as $98 with coupons. These prices are above the $35 cash-pay price for Tresiba with a GoodRx-type coupon, meaning Tresiba is actually cheaper at the point of sale for many cash-pay patients, despite its higher list price.

This counterintuitive pricing dynamic occurs because Novo Nordisk aggressively negotiates pharmacy benefit manager rebates for Tresiba, which sometimes results in larger retail discounts than glargine biosimilars receive. A BMJ analysis of insulin pricing dynamics documented this pattern across multiple branded insulins and found that list price is a poor predictor of actual patient cost. A complementary NEJM analysis found similar misalignment between list prices and net prices across the insulin category.

Clinically, DEVOTE showed a 40% reduction in severe nocturnal hypoglycemia for insulin degludec versus glargine U-100 [1]. For a Tennessee patient with a history of hypoglycemia-related falls, driving impairment, or employment in safety-sensitive jobs, that difference may outweigh a marginal cost differential. The Endocrine Society guidelines support individualized basal insulin selection based on hypoglycemia risk, which means Tresiba is often the medically justified choice even for cost-sensitive patients. Additional outcomes data from a real-world PubMed registry study confirmed that insulin degludec users experienced fewer hypoglycemia-related emergency contacts than matched glargine users in a Nordic health registry.

What Novo Nordisk Savings Programs Apply in Tennessee?

Novo Nordisk operates three programs relevant to Tennessee patients in 2026.

The My$99Insulin program caps monthly Tresiba cost at $99 for commercially insured patients who present the savings card at participating Tennessee pharmacies. No application is required beyond registering at the Novo Nordisk website or using the printed card. This program has applied since 2021 and has not been withdrawn as of early 2025. CMS data on manufacturer assistance programs note that such programs are available only for commercially insured patients and explicitly exclude Medicare Part D and Medicaid, consistent with federal anti-kickback statute requirements.

The Novo Nordisk Patient Assistance Program (NovoCare PAP) provides free Tresiba to uninsured and underinsured Tennessee residents who meet income criteria. Documentation requirements include the most recent federal tax return or proof of income, a completed enrollment form, and a prescriber's signature. The NIH MedlinePlus page on patient assistance programs provides general guidance on navigating these programs.

The Ready, Set, Save program offers a 30-day free trial of Tresiba for new commercially insured patients who have never used it before. A Tennessee prescriber can activate this through the Novo Nordisk representative system or the prescriber portal. FDA transparency about manufacturer programs applies to how these are promoted.

Separately, the American Diabetes Association's insulin access resources list additional state-level and nonprofit programs that Tennessee residents can stack with manufacturer programs in some cases.